The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development
- 27 May 2009
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 86 (1), 32-43
- https://doi.org/10.1038/clpt.2009.69
Abstract
The acceptance and use of either surrogate end points (SEPs) or efficient clinical end points are associated with greater and more rapid availability of new medicines as compared with disease situations for which clinical end points are inefficient or no surrogates exist. This review of the history of the development, qualification, and acceptance of key SEPs shows that both successes and failures had three key characteristics: (i) apparent biologic plausibility, (ii) prognostic value for the outcome of the disease, and (iii) an association between changes in the SEP and changes in outcome with therapeutic intervention--the three factors recommended for SEPs in the International Conference on Harmonisation's "Statistical Principles for Clinical Trials." We recommend that only prognostic value be an absolute prerequisite for surrogacy, because therapeutic interventions may not exist a priori, and biological plausibility can be subjective. Ideally, all three of these factors would be traded off against one another in a consistent and transparent risk-management process.Keywords
This publication has 41 references indexed in Scilit:
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, StrategiesAnnual Review of Pharmacology and Toxicology, 2001
- Contributions of the framingham study to the conquest of coronary artery diseaseThe American Journal of Cardiology, 1988
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Effect of the Fluoride/Calcium Regimen on Vertebral Fracture Occurrence in Postmenopausal OsteoporosisNew England Journal of Medicine, 1982
- Symposium on Research on Acute Myocardial InfarctionCirculation, 1970
- THE ROLE OF BLOOD-PRESSURE CONTROL IN PREVENTING COMPLICATIONS OF HYPERTENSIONThe Lancet, 1964